A new obesity framework reveals hidden health risks in people with normal BMI and urges a shift in diagnosis from ...

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.

Northwestern Medicine has launched a program to help patients who have concerns related to obesity and are planning a pregnancy. Women with higher levels of body fat sometimes struggle to conceive ...

As a registered dietitian, President of the California Academy of Nutrition and Dietetics, and proud Chico State alumna, I am deeply concerned about the recent passage of federal budget cuts target… ...

Few studies have looked at early school start times for young children. Two recent studies show that with early starts, sleep and health were compromised.

Syntis Bio, Inc. (Syntis), a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes and rare diseases, announced today ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research materials to sidestep regulatory scrutiny.

Blue-green algae that can produce harmful toxins bloom in Lake Erie each year, nurtured by phosphorus runoff from farm operations.

NOAA and its research partners are forecasting a mild to moderate harmful algal bloom (HAB) in western Lake Erie this summer. This year's bloom is expected to measure 3 on the HAB severity index ...

On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development.

Amgen's new drug MariTide shows promise in obesity treatment, with participants losing up to 16% body weight in a year with monthly shots.